Amid a structural shift towards Asia, Insilico Medicine's IPO in December was a significant moment for the exchange, while French biotech TheraVectys is understood to be considering a listing.
As Hong Kong's primary debt market continues to be attractive, underwriters said the bond will provide a reliable benchmark for future HKD-denominated offerings.
The offerings attracted public sector institutions, banks, asset managers, corporates and private banks, with particularly strong participation from Asia.
The spun off firm from JD.com is preparing for an initial public offering on the Hong Kong Stock Exchange on December 11; the deal could generate around $20m of fees.